Hematopoiesis News 8.30 August 1, 2017 | |
| |
TOP STORYGut Viruses Tied to Potentially Deadly Complication of Bone Marrow Transplant A virus hiding quietly in the gut may trigger the onset of a severe complication known as graft-versus-host disease in patients who receive bone marrow transplants, according to a new study. [Press release from the University of California, San Francisco discussing online prepublication in Nature Medicine] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Regulation of Drosophila Hematopoietic Sites by Activin-β from Active Sensory Neurons Investigators report that activin-β, a transforming growth factor-β family ligand, is expressed by sensory neurons of the peripheral nervous system (PNS) and regulates the proliferation and adhesion of hemocytes. These hemocyte responses depended on PNS activity, as shown by agonist treatment and transient silencing of sensory neurons. [Nat Commun] Full Article The JAK2V617F-Bearing Vascular Niche Promotes Clonal Expansion in Myeloproliferative Neoplasms Researchers showed that the JAK2V617F-bearing vascular niche promotes the expansion of the JAK2V617F hematopoietic stem/progenitor cells (HSPCs) in preference to JAK2WT HSPCs, potentially contributing to poor donor cell engraftment and disease relapse following stem cell transplantation. The expression of chemokine ligand 12 and stem cell factor were up regulated in JAK2V617F-bearing endothelial cells (ECs) compared to wild type ECs. [Leukemia] Abstract DNA Damage Tolerance in Hematopoietic Stem and Progenitor Cells in Mice To investigate the role of DNA damage tolerance (DDT) in maintaining HSCs and progenitors, the authors used PcnaK164R/K164R mice as a unique DDT-defective mouse model. Analysis of the composition of HSCs and HSC-derived multipotent progenitors (MPPs) revealed a significantly reduced number of HSCs, likely owing to increased differentiation of HSCs toward myeloid/erythroid-associated MPP2s. [Proc Natl Acad Sci USA] Full Article p53 Mediates Failure of Human Definitive Hematopoiesis in Dyskeratosis Congenita Researchers used the directed differentiation of human embryonic stem cells harboring clinically relevant mutations in telomerase to understand the consequences of dyskeratosis congenita (DC)-associated mutations on the primitive and definitive hematopoietic programs. Telomere shortening did not broadly impair hematopoiesis, as primitive hematopoiesis was not impaired in DC cells. [Stem Cell Reports] Full Article | Press Release | Graphical Abstract Scientists characterized myeloid leukemia factor (MLF)’s mode of action in Drosophila blood cells using proteomic, transcriptomic and genetic approaches. Their results showed that MLF and the Hsp40 co-chaperone family member DnaJ-1 interact through conserved domains and they demonstrated that both proteins bind and stabilize Lozenge in cell culture. [PLoS Genet] Full Article Accumulated evidence supports the potent stimulating effects of multiple small molecules on the expansion of HSCs, which are important for the therapy of various hematological disorders. Investigators report a novel, optimized formula, named the SC cocktail, which contains a combination of three such small molecules and four cytokines. [Stem Cell Res Ther] Full Article The authors studied the effects of the inosine-5’-monophosphate dehydrogenase inhibitor FF-10501 on erythropoiesis of human hematopoietic cells. Differentiation of K562 chronic myeloid leukemia cells to an erythroid lineage was promoted by FF-10501 in a dose-dependent manner. [Leuk Lymphoma] Full Article The role of septin 6 in hematopoiesis and whether it is involved in scaffolds within hematopoietic cells is not known. Septin 6 deficient HSCs presented with an increased engraftment potential but altered lymphoid differentiation with a reduced contribution to the T cell compartment and an increased B cell contribution. [Exp Hematol] Abstract CLINICAL RESEARCHScientists report their efforts to induce pluripotency from the heterogeneous population of human patients that represents acute myeloid leukemia (AML) in the clinic. Using robust optimized reprogramming methods, they demonstrated that reprogramming of AML cells harboring leukemic genomic aberrations is a rare event with the exception of those with de novo mixed-lineage leukemia mutations that can be reprogrammed and model drug responses in vitro. [Stem Cells] Abstract Researchers assessed all toxicities ≥ grade 3 from the start of conditioning to date of death, relapse, or last contact in 200 patients during the first year post-transplantation, identifying 1885 individual toxicities among 17 organ-based toxicity groups. The most prevalent toxicities in the first year were of infectious, metabolic, hematologic, oral/GI, hepatic, cardiac and pulmonary etiologies. [Biol Blood Marrow Transplant] Abstract | |
| |
REVIEWSBeyond mRNA: The Role of Non-Coding RNAs in Normal and Aberrant Hematopoiesis The authors overview the broad categories of non-coding ribonucleic acids and discuss a few examples regulating normal and aberrant hematopoiesis. [Mol Genet Metab] Abstract Changes of Meibomian Glands in the Early Stage of Post Hematopoietic Stem Cell Transplantation Scientists discuss various changes in the meibomian glands and ocular surface, and tear dynamics in the early stage following hematopoietic stem cell transplantation. [Exp Eye Res] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
INDUSTRY NEWSCTI BioPharma Corp. announced that the first patient has been enrolled in PAC203, a Phase II clinical trial of pacritinib in patients with primary myelofibrosis who have failed prior ruxolitinib therapy. [CTI BioPharma Corp.] Press Release NantKwest Inc. announced the final results of a Phase I clinical trial of the company’s activated NK (aNK) cell therapy platform in relapsed hematological malignancies. [NantKwest Inc.] Press Release Celgene Corporation and Agios Pharmaceuticals, Inc. announced that IDHIFA® was granted approval from the U.S. FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test. [Celgene Corporation] Press Release Ablynx announced that the U.S. FDA has granted Fast Track designation for caplacizumab, the company’s first-in-class anti-von Willebrand factor Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (TTP). [Ablynx] Press Release Trovagene, Inc. announced that the U.S. FDA has accepted its Investigational New Drug Application for PCM-075, a polo-like kinase 1 inhibitor, and has provided authorization to proceed with the treatment of patients with AML. [Trovagene, Inc.] Press Release Four Young Pediatric Cancer Research Fellows Earn $1 Million in Awards The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon-Sohn Pediatric Cancer Fellowship Award, committing nearly $1 million to help address a critical shortage of funding for pediatric cancer research. [The Damon Runyon Cancer Research Foundation] Press Release St. Baldrick’s Awards Eight Faculty with Cancer Research Grants The St. Baldrick’s Foundation has announced its 2017 summer grant recipients, including eight from Baylor College of Medicine and Texas Children’s Cancer Center. [Baylor College of Medicine] Press Release | |
| |
POLICY NEWSUniversity of Tokyo Probe Says Chromosome Team Doctored Images After a nearly year-long investigation into anonymous allegations of data and image falsification in numerous papers, a University of Tokyo committee announced it had confirmed that one research group falsified images and graphs in five papers. The panel cleared five other research groups of wrongdoing. [ScienceInsider] Editorial Why Would a University Pay a Scientist Found Guilty of Misconduct to Leave? In June 2016, investigators at the University of Georgia in Athens concluded that Azza El-Remessy, a faculty member who studied the impact of diabetes on the eye, had committed misconduct and recommended she be terminated. El-Remessy hired a lawyer to dispute the findings, but the following October she gave up her challenge after the university paid her $100,000—essentially to leave. [ScienceInsider] Editorial
| |
EVENTSNEW 7th InterAmerican Oncology Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Assistant – Myeloid Neoplasias (University of Oxford) Postdoctoral Research Fellow – Metabolic Diseases & Hematological Malignancies (Columbia University) Postdoctoral Fellow – Epigenetics and Immune Signaling in Cancer (Thomas Jefferson University) Postdoctoral Fellow – Regenerative Medicine (Loma Linda University) Postdoctoral Fellow – Epigenetics of Hematopoiesis (International Clinical Research Center) Postdoctoral Associate – Normal and Malignant Hematopoiesis (University of Miami) PhD Studentship – Genome Editing of Hematopoietic Stem Cells (CHU Saint Justine Research Center) Associate Director, Clinical Development – Hematology/Oncology (Jazz Pharmaceuticals) Postdoctoral Fellow – Single Cell Sequencing (University of British Columbia Mechanical Engineering) Postdoctoral Position – Experimental Leukemia Research (University Children’s Hospital Basel) Lab Director – Pharmacokinetics (Seattle Cancer Care Alliance) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|